You are here: Industry Insights > Ronapreve

News List

Cocktail COVID-19 Neutralizing Antibody was Officially Approved in Japan to Build a Second Line of Defense PharmaSources/Xiaoyaowan
August 02, 2021
Recently, Ronapreve, a product of Roche Pharmaceuticals, was approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of mild to moderate COVID-19 patients by intravenous infusion.
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 WorldPharmaNews
February 15, 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification.
European Commission approves Ronapreve to treat non-hospitalised COVID-19 patients ExpressPharma
November 17, 2021
Roche recently announced that the European Commission has granted a marketing authorisation for Ronapreve (casirivimab and imdevimab) for treating COVID-19 in adults and adolescents...
EC approves Roche’s Ronapreve for Covid-19 treatment Pharmaceutical-Business-Review
November 16, 2021
The European Commission (EC) has granted marketing authorisation for Roche’s Ronapreve to treat non-hospitalised Covid-19 patients aged 12 years and above.
EMA endorses two monoclonal antibody medicines for COVID-19 EuropeanPharmaceuticalReview
November 15, 2021
The European Medicines Agency (EMA)’s human medicines committee, the Committee for Medicinal Products for Human Use (CHMP), has recommended authorising Ronapreve™ ...
EMA CHMP recommends authorisation of Roche-Regeneron’s Covid-19 therapy Pharmaceutical-Technology
November 15, 2021
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the EU approval of Roche and Regeneron’s Ronapreve...
CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease WorldPharmaNews
November 12, 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the antibody...
Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 worldpharmanews
July 26, 2021
Roche announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve™ (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion.
Japan First to Approve Roche’s Ronapreve to Treat COVID-19 contractpharma
July 22, 2021
Roche received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Ronapreve (casirivimab and imdevimab), for the treatment of mild to moderate COVID-19 via intravenous infusion.
Chugai Pharma obtains regulatory approval for anti-SARS-CoV-2 monoclonal antibody Ronapreve expresspharma
July 21, 2021
The special approval for emergency under article 14-3 of the Pharmaceuticals and Medical Devices Act was applied to this approval.